Foghorn Therapeutics (FHTX) Cash from Operations Growth (3y) (2022 - 2026)

Foghorn Therapeutics (FHTX) Cash from Operations Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -5.07%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 33.08%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -7.60%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Foghorn Therapeutics 352.57 Mn 263.66 Mn - 6.77%

Historic Data

Download Data
DateValue
Mar 31, 2026 6.77%
Dec 31, 2025 8.34%
Sep 30, 2025 1.91%
Jun 30, 2025 10.21%
Mar 31, 2025 -27.82%
Dec 31, 2024 -59.58%
Sep 30, 2024 -0.81%
Jun 30, 2024 -11.38%
Mar 31, 2024 -8.23%
Dec 31, 2023 -37.24%
Sep 30, 2023 -128.83%
Jun 30, 2023 -36.70%
Mar 31, 2023 -42.56%
Dec 31, 2022 -29.94%